Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : FibroBiologics
Deal Size : Undisclosed
Deal Type : Collaboration
FibroBiologics and Charles River Partner for Fibroblast Cell-Based Therapies
Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).
Product Name : CYWC628
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : FibroBiologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cannabidiol
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers
Details :
Product Name : CYP-006TK
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Podiatry
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte
Details :
Product Name : CYP-006TK
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Cymerus Mesenchymal Stem Cell
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable